AETHLON MEDICAL INC (AEMD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$1.82-5.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · AEMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -15.8% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 71.2% |
Growth built into the price is above our model estimate.
The price assumes 87.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
AEMD — capital allocation — Material Modification to Rights of Security
Dated 2026-07-31
Material Modification to Rights of Security Holders. On Jul y 30, 2026, Aethlon Medical, Inc., a Nevada corporation (the “Company”), filed a Certificate of Change (the “Certificate of Change”) pursuant to Section 78.209 of the Nevada Revised Statutes (“NRS”) with the Secretary of State of the State of Nevada authorizing a 1-for-5 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, $0.001 par value per share (the “Common Stock”). The…
Why it matters: Finishing this group is important. It helps us see how well the Hemopurifier works for cancer.
Supportive ifThe third group finishes enrolling and treating all planned participants. There are no safety problems.
Worry ifThere are delays in enrollment or treatment, or safety issues arise in the group.
Why it matters: Managing costs will help the company stay healthy and keep running.
Supportive ifOperating costs drop from $1.6 million in Q2 2026.
Worry ifOperating costs rise or stay the same, showing bad cost management.
Why it matters: The success of this offering is key for funding operations and clinical trials. It shows investor trust.
Supportive ifThe offering closes well, and funds go to clinical trials as planned.
Worry ifThe offering does not close, or funds are misused, raising worries about financial health.
Why it matters: This report will give details on financial performance and future plans.
Watch forThe earnings report shows revenue growth is speeding up or is better than expected.
Also watch forEarnings report shows revenue drops or misses expectations.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$381 on $10,000 · ±3.8% | How much price usually moves either way. |
| Bad day | $1,061 loss on $10,000 · 10.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,544 loss on $10,000 · 95.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Better cash flow shows stronger financial health and better loss management.
Supportive ifCash flow from operations improves to less than negative $1.5 million.
Worry ifCash flow from operations remains worse than negative $1.5 million.
Why it matters: More capital helps Aethlon Medical with operations and growth plans.
Supportive ifTotal capital from ATM offerings is over $2 million.
Worry ifCapital raised through ATM offerings is less than $1 million.
Why it matters: Updates on stock offerings show how the company handles its money needs.
Watch forA new ATM equity offering was announced. It is over $1 million.
Also watch forNo announcements or delays in planned ATM offerings.
Why it matters: Successful fundraising will help research and keep the company stable.
Supportive ifThe company closes the $4.0 million offering and uses the money as planned.
Worry ifThe offering fails to close or proceeds are not used for intended purposes.
Why it matters: Worsening losses would show that cash flow management is not improving. This could raise concerns about the company's financial health.
Worry ifOperating losses are more than $1.9 million in Q4 2026.
Less concerning ifOperating losses improve to less than $1.9 million in Q4 2026.
Why it matters: Earnings results show how well the company is doing. This matters for investor feelings.
Watch forThe earnings report shows a big rise in revenue or smaller losses.
Also watch forThe earnings report shows ongoing losses or falling revenue.
Why it matters: Watching cash burn shows the company's financial health and how well it can operate.
Worry ifOperating costs stay below $1.6 million in the next quarters.
Less concerning ifOperating costs go over $1.6 million, showing higher cash burn.
Why it matters: Worsening losses would show that Aethlon Medical is struggling to manage costs and cash flow.
Worry ifQ2 results show losses over negative $2 million.
Less concerning ifQ2 results show losses better than negative $1.5 million.
Why it matters: New patents could help the Hemopurifier's market potential. They protect its ideas.
Supportive ifNew patents are announced for more uses of the Hemopurifier.
Worry ifNo new patents or IP expansions announced in the next quarter.